RayzeBio (RayzeBio) Days Payable : 0.00 (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is RayzeBio Days Payable?

RayzeBio's average Accounts Payable for the three months ended in Sep. 2023 was $2.34 Mil. RayzeBio's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for RayzeBio's Days Payable or its related term are showing as below:

RYZB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.28
* Ranked among companies with meaningful Days Payable only.

RayzeBio's Days Payable stayed the same from Jun. 2022 (0.00) to Sep. 2023 (0.00). stayed the same

RayzeBio Days Payable Historical Data

The historical data trend for RayzeBio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RayzeBio Days Payable Chart

RayzeBio Annual Data

Trend

Dec20

Dec21

Dec22

Days Payable

RayzeBio Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23
Days Payable	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of RayzeBio's Days Payable

For the Biotechnology subindustry, RayzeBio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RayzeBio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RayzeBio's Days Payable distribution charts can be found below:

* The bar in red indicates where RayzeBio's Days Payable falls into.

RayzeBio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

RayzeBio's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (1.127	+	2.623)	/	2 )	/	0	*	365
=	1.875					/	0	*	365
=	N/A

RayzeBio's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

	Days Payable (Q: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (2.433	+	2.237)	/	2 )	/	0	*	365 / 4
=	2.335					/	0	*	365 / 4
=	N/A

RayzeBio Days Payable Related Terms

Thank you for viewing the detailed overview of RayzeBio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

RayzeBio (RayzeBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RayzeBio inc (NAS:RYZB) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

5505 Morehouse Drive, Suite 300, San Diego, CA, USA, 92121

Website

https://www.rayzebio.com

RayzeBio inc is a company operating as vertically integrated radiopharmaceutical therapeutics company. The main objective of the company is defeating cancer with radiopharmaceutical medicines. It has a created a pipeline of multiple drug candidates, in therapeutic areas with significant market opportunities. They have a portfolio of potential RPT drug and development candidates that includes late-stage clinical programs, development programs and discovery programs.

Executives

Hauwermeiren Timothy Van	director	C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Maha Katabi	director	SOFINNOVA INVESTMENTS, 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Viking Global Opportunities Drawdown Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Drawdown Portfolio Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Arvind Kush	officer: Chief Financial Officer	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Wellington Biomedical Innovation Master Investors (cayman) Ii L.p.	10 percent owner	280 CONGRESS STREET, BOSTON MA 02210
Versant Ventures Vii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kenneth Song	director, officer: President and Chief Executive	C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Susan Moran	officer: Chief Medical Officer	1232 RICHARDSON AVE, LOS ALTOS CA 94024
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Redmile Biopharma Investments Ii, L.p.	10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129